


SWIXX SIGNS AGREEMENT WITH KRYSTAL BIOTECH FOR VYJUVEK® GENE THERAPY FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

Baar, Switzerland, September 25th, 2024 – Swixx BioPharma AG of Baar, Switzerland, announced today the signature of a Distribution Agreement with Krystal Biotech, Inc. Under the Agreement, Swixx is appointed to exclusively distribute and commercialize VYJUVEK® (beremagene geperpavec-svdt) in the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.

VYJUVEK® is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB), a rare and severe disease that affects the skin and mucosal tissues¹. DEB is caused by mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, which leads to extremely fragile skin that blisters and tears from minor friction or trauma. VYJUVEK, a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A gene when applied directly to DEB wounds, was approved by the U.S. FDA in May 2023 and a Marketing Authorization Application is currently under evaluation by the European Medicines Agency (EMA).²

 **Dr. Dezso Martha**, COO of Swixx European markets, welcomed the new relationship, commenting that “dystrophic epidermolysis bullosa is a rare and painful genetic skin condition and VYJUVEK is the only treatment designed to address the fundamental disease-causing mechanism of DEB at the molecular level. It is a great privilege to be able to bring VYJUVEK to CEE patients, many of whom are children or young adults. We look forward to working closely with Krystal and the medical community to accelerate patient access to this life-changing medicine as quickly as possible. We are honoured to work with such innovative, new therapies and sincerely thank Krystal for selecting Swixx for partnership.”

About Swixx BioPharma AG

Swixx operates 44 subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East and via Biopas, a Swixx BioPharma company, in almost 20 countries in Latin America. After the acquisition of Biopas, Swixx group now has over 1,600 employees and sales which is likely to exceed 1.1 billion Euros in 2024. The company is one of the fastest-growing and largest independent commercialization platforms for biopharma. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.



**1000 EUROPE'S
FASTEST GROWING
COMPANIES 2024**



Contact:

Vedrana Sokac Brataljenovic, Public Affairs Director,

vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

References:

¹Food and Drug Administration. Available at: <https://www.fda.gov/vaccines-blood-biologics/vyjuvek>. Last accessed: September 2024.

²Krystal Biotech. Available at: <https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-ema-validation-marketing-authorization>. Last accessed: September 2024.

